Pharmacokinetic Interaction Trial of Clofutriben With Midazolam and Prednisolone

Sparrow Pharmaceuticals16 enrolled

Overview

Drug: 2 single oral doses of midazolam, 2 single oral doses of prednisolone , and clofutriben once daily for 16 days.

Approximately 16 healthy male and female participants will be enrolled at a single center in the US. Each participant will receive 2 single oral doses of midazolam , 2 single oral doses of prednisolone, and clofutriben once daily for 16 days. On each day that midazolam is administered, blood samples for midazolam analysis in plasma will be collected for 24 hours. On each day that prednisolone is administered, blood samples for prednisolone, prednisone, and 6β-hydroxyprednisolone analyses in plasma will be collected for 24 hours. Blood samples for clofutriben and metabolite (AS2570469) analyses in plasma will be collected for 24 hours after the first dose and during 2 intervals at steady state. Blood samples for cortisol and cortisone analyses will be collected for 24 hours after administration of prednisolone, clofutriben, and both trial interventions together, and prior to dosing of either trial intervention. Urine will be collected for analysis of clofutriben, prednisolone, and metabolites. Feces will be collected for analysis of clofutriben and metabolites. Safety and tolerability will be assessed.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Healthy Participants

Interventions

midazolamDRUG

Drug: 2 single oral doses of midazolam ,

clofutriben once daily for 16 daysDRUG

clofutriben once daily for 16 days

2 single oral doses of prednisoloneDRUG

2 single oral doses of prednisolone

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female participants aged 18 to 75 years of age, * Body mass index of 18 to 35 kg/m2, * Taking no medications, * Are considered by the investigator to be in good general health. Exclusion Criteria: * In the opinion of the investigator, the participant is not suitable for entry into the trial or has any contraindication to midazolam or prednisolone.

Locations (1)

PPD Austin Research Unit

Austin, Texas, United States

Outcomes

Primary Outcomes

Cmax of midazolam.

It will be concluded that there is no relevant interaction of clofutriben on midazolam if the 90% CIs for the Cmax ratios (midazolam + clofutriben)/midazolam alone) are contained within the \[80%, 125%\] interval.

Time frame: 24 hours from dose

AUC0-t of midazolam

: It will be concluded that there is no relevant interaction of clofutriben on midazolam if the 90% CIs for the AUC0-t (midazolam + clofutriben)/midazolam alone) are contained within the \[80%, 125%\] interval.

Time frame: 24 hours from dose

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.